eMIMS New Product

New drug - Tasigna

23-Jun-08

Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome positive chronic myelogenous leukaemia (CML).

Treatment is indicated for adults with chronic-phase and accelerated-phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.

View Tasigna drug record

Further information: Novartis 01276 692255

Comments

Only registered users may comment. Log in now or register for a free account.

Tools

Add this article to my storage folder
Print this article
Send this article to a friend
Show all comments about this article
Comment on this article
RSS feeds
Sign up for email bulletins

Latest Guidelines

Diabetes: Continuous Subcutaneous Insulin Infusion - Update (NICE)
Obesity and Overweight, Adult: Rimonabant (NICE)
Psoriasis, Treatment of Adults: Adalimumab (NICE)
Cancer, Head and Neck: Cetuximab (NICE)
Cardiovascular Disease (CVD), Lipid Modification for the Prevention of (NICE)

Search all Guidelines

GMS Contract Action Plan

Asthma
Atrial Fibrillation
Cancer
Chronic Obstructive Pulmonary Disease
Coronary Heart Disease (Secondary Prevention)

Show all GMS Contract Action Plans

Jobs

Job of the Week

Medicines Management Pharmacists South East England
Community Senior Pharmacy Technician South East England

Conversion Calculators

Baby's Age
Body Mass Index (BMI)
Body Surface Area
Creatinine Clearance (CrCl)
Height
Liquid
Pregnancy
Temperature
Urea & Electrolytes (U&Es)
Weight